Similar to the above results measuring overall cell proliferation by SRB or MTT assays in vitro, we saw no difference in responsiveness to 17-AAG between BAX+/− and BAX−/− HCT116 cells when grown in vivo as solid tumor xenografts in immune-compromised mice, as measured by tumor volume or final tumor weight. The gene discussed is BAX; the disease is neoplasm.